ÉèΪÊ×Ò³ ¼ÓÈëÊÕ²Ø

TOP

VEEN-3G INJ 500mL(´×ËáÄÆ/ÆÏÌÑÌÇ×¢Éä¼Á,¥ô¥£©`¥ó£³£ÇݔҺ)
Ò©µê¹ú±ð£º  
²úµØ¹ú¼Ò£º ÈÕ±¾ 
´¦ ·½ Ò©£º ÊÇ 
ËùÊôÀà±ð£º 500ºÁÉý/Æ¿ 20Æ¿/ºÐ 
°ü×°¹æ¸ñ£º 500ºÁÉý/Æ¿ 20Æ¿/ºÐ 
¼Æ¼Ûµ¥Î»£º ºÐ 
Éú²ú³§¼ÒÖÐÎIJο¼ÒëÃû:
ÅdºÍÖêʽ»áÉç
Éú²ú³§¼ÒÓ¢ÎÄÃû:
KOWA
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·1:
http://www.kegg.jp/medicus-bin/japic_med?japic_code=00060283
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·2:
http://www.info.pmda.go.jp/go/pack/3319562A2045_1_02/
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·3:
Ô­²úµØÓ¢ÎÄÉÌÆ·Ãû:
VEEN-3G INJ(¥ô¥£©`¥ó) 500ml/bag 20bags/box
Ô­²úµØÓ¢ÎÄÒ©Æ·Ãû:
SODIUM ACETATE/GLUCOSE
ÖÐÎIJο¼ÉÌÆ·ÒëÃû:
VEEN-3G×¢Éä¼Á(¥ô¥£©`¥ó) 500ºÁÉý/Æ¿ 20Æ¿/ºÐ
ÖÐÎIJο¼Ò©Æ·ÒëÃû:
´×ËáÄÆ/ÆÏÌÑÌÇ
ÔøÓÃÃû:
¼ò½é£º

 

²¿·ÝÖÐÎÄ´×ËáÄÆ/ÆÏÌÑÌÇݔҺ´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©
ÉÌÆ·Ãû³Æ:Veen-3G Inj.
Ó¢ÎÄÃû³Æ:SODIUM ACETATE/GLUCOSE
ÖÐÎÄÃû³Æ:´×ËáÄÆ/ÆÏÌÑÌÇݔҺ
Éú²ú³§¼Ò:ÅdºÍÖêʽ»áÉç
ҩЧ·ÖÀà
ѪҺÖƼÁ
Åú×¼ÈÕÆÚ£º2012Äê6ÔÂ
É̘ËÃû
Veen-3G Inj.
´¦ÀíÉϵÄ×¢Òâ
²»ÒªµôÏÂÀ´»òÊǸø±ðÈË´øÀ´ºÜ´óµÄ³å»÷¡£ÈÝÆ÷ÓпÉÄÜÊÇË𻵵ÄÔ­Òò¡£
Ò×À­¹ÞÆÆËðµÄ¶«Î÷²»ÒªÊ¹Óá£
ËäÈ»²»ÐèÒª¿ÕÆøÕë(airÕë)£¬µ«Èç¹ûÒ©ÒºµÄÁ¿¼õÉÙ£¬ÅÅÆøËٶȾͻáϽµ£¬ËùÒÔҪעÒâµÎµÎËٶȡ£ÁíÍ⣬ΪÁ˳ä·Ö±£³ÖÒ©ÒºÃæÓë¾²ÂöÕëÖ®¼äµÄÂä²î£¬ÔÚµãµÎÖнøÐдòµãµÎ¡£
²»ÒªÓÃu×Ö¹ÜÁ¬Ðø×¢Éä¡£
²Ù×÷³ÌÐò
È¡µÃËÜÁÏƿװ(r)µÄpultop¡£
ÔÚ±¾Ò©¼ÁÖлìºÏÆäËûÒ©¼ÁµÄÇé¿öÏ£¬Òª½«×¢ÉäÕë´¹Ö±µØ²åÔÚÏðƤÈûµÄÕë´Ì²¿(С)ÉÏ£¬²»ÒªÖظ´´ÌÉËͬһ²¿Î»¡£
ÔÚÍêÈ«·ÅËÉǯλµÄ״̬Ï£¬½«µÎÒºµÄÒºÕë´¹Ö±µØ´ÌÔÚÏðƤÈûµÄÕë´ÌÉÏ¡£
¹Ø±Õǯ¿Ú£¬µõÈÝÆ÷£¬²¢ÔÚµõƿͲÄÚÅçÈëÔ¼1/3¡£
´ò¿ªÇ¯¿Ú£¬½«Ò©Ë®Á÷³öÀ´£¬½«Èí¹ÜÄڵĿÕÆøÈ«²¿Çå³ý£¬²¢½«Èí¹Ü·âÉÏ¡£
´©Í¸¾²ÂöÕëºó£¬Ö𽥿ØÖÆǯλ»ºÂýµÄµÎÂäËٶȣ¬¿ªÊ¼µãµÎ¾²×¢¡£
ÈÝÆ÷µÄ¿Ì¶È´ó¸Å×÷Ϊ»ù׼ʹÓá£
200mL£º½M³É
ÓЄ¿³É·Ö£¨200mL£©
ÆÏÌÑÌÇ10.0 g
292.2ºÁ¿ËÑλ¯ÄÆ
104.4ºÁ¿ËÑλ¯¸Æ
101.7ºÁ¿ËÂÈ»¯Ã¾
Á×Ëá¶þÇâ¼Ø272.2ºÁ¿Ë
ÒÒËáÄÆË®ºÍÎï544.3mg
Ìí¼ÓÎï
phÖµµ÷¼Á
µç½âÖÊ×é³É(meq/l)
na +: 45k +:17mg2 +:5cl-37h2po4 -:10ch3coo -: 20
ÐÔ×´
͸Ã÷×´ÎÞÉ«~΢»ÆÉ«Ç峺ҺÌå
phÖµ4.3
½þ͸ѹ±ÈÔ¼1.5(±ÈÉúÀíʳÑÎÒº)
500ºÁÉý:ÖØ×é
ÓЄ¿³É·Ö£¨500mL£©
ÆÏÌÑÌÇ25.0g
730.6mg261.0mg
¶þÂÈ»¯Ã¾
680.5mgÁ×Ëá¶þÇâ¼Ø
ÒÒËáÄÆË®ºÍÎï1360.8ºÁ¿Ë
Ìí¼ÓÎï
phÖµµ÷¼Á
µç½âÖÊ×é³É(meq/l)
Na£«£º45
K£«£º17
Mg2£«£º5
Cl-£º37
H2PO4-£º10
CH3COO-£º20
ÐÔ×´
͸Ã÷×´ÎÞÉ«~΢»ÆÉ«Ç峺ҺÌå
phÖµ4.3
½þ͸ѹ±ÈÔ¼1.5(±ÈÉúÀíʳÑÎÒº)
ҩЧҩÀí
½«¼¢¶ö¾øʳʱÕë¶ÔÍÃ×ӵı¾Ò©¼ÁµÄЧ¹ûÓëÂíÌØËÕ¼ÓÒÒËáõ¥Î¬³ÖÒº¡¢ÆÏÌÑÌǼÓÈéËáά³ÖÒº¼°ÒÒËáά³ÖÒº½øÐбȽϵĽá¹ûÊÇ£¬ÌåÖر仯¡¢ÄòÒºÁ¿¡¢Ë®·Ö¼°µç½âÖÊƽºâÎÞÃ÷ÏÔ²îÒì¡£
ÊÊÓ¦Ö¢
µ±¿Ú·þ½û±Õ»ò²»¹»µÄʱºò£¬±£³ÖË®·Ö¡¢µç½âÖÊ¡¢²¹³äÄÜÁ¿
Ó÷¨ÓëÓÃÁ¿
Ò»°ãÇé¿öÏ£¬³ÉÈËÿһ´Î×¢500 ~ 1000ml£¬Ð¡¶ùÿһ´Î×¢200 ~ 500ml¡£³ÉÈ˺ͶùͯµÄ×¢ÉäËÙ¶ÈΪÿСʱ0.5g/kgÒÔÏÂ1Сʱ£¬¾ùΪÆÏÌÑÌÇ¡£ÁíÍ⣬¸ù¾ÝÄêÁä¡¢Ö¢×´¡¢ÌåÖصÈÊʵ±Ôö¼õ¡£
ÁÙ´²³É¼¨
ÒÔ¾­¿Ú¡¢¾­³¦²»ÄÜÉãÈë»ò²»³ä·ÖµÄ»¼Õß¹²¼Æ201¸öÀý×ÓΪ¶ÔÏ󣬶ÔÑ­»·¶¯Ì¬ÐÔ¡¢Ë®·Ö¡¢µç½âÖʵÄά³ÖÒÔ¼°ÌǵÄÀûÓõĸ÷ÏîÄ¿½øÐзÖÊý»¯£¬²¢ÔÚÆäºÏ¼Æ·ÖÊýÉÏ£¬¶ÔÆäÓÐЧÐÔ½øÐÐÁËÆÀ¹À¡£
©–±È½ÏʵÑéÔÚÏû»¯Æ÷¹ÙÄÚ¿ÆÁìÓò(10¸öÉèÊ©)ʵʩ£¬ÔÚ±¾Ò©¼Á(66¸öÀý×Ó)ºÍ¶ÔÕÕ¼Á(65Àý)ÖгÐÈÏÁËͬÑù³Ì¶ÈµÄÓÐЧÐÔ¡£µ«ÊÇ£¬×÷Ϊ¶ÔÕÕ¼ÁµÃµ½ÈϿɵÄÄòÌÇÅÅйÊÇÔÚ±¾Ò©¼ÁÖм¸ºõ²»±»ÈϿɵÄ4)¡£
©–Ò»°ãÁÙ´²ÊÔÑéÔÚÉöÔàÄÚ¿Æ(4¸öÉèÊ©:20¸öÀý×Ó)¡¢Íâ¿Æ(8¸öÉèÊ©:66Àý)ÒÔ¼°¶ù¿ÆÁìÓò£¬ÔÚ¶ùͯÂé×í¿Æ(1¸öÉèÊ©:24Àý)¼°¶ùͯÍâ¿Æ(1¸öÉèÊ©:25Àý)½øÐÐÁË¡£½á¹ûÈ«¶¼³ÐÈÏÆäÓÐЧÐÔ¡£
°ü×°
¥ô¥£©`¥ó£³£ÇݔҺ¡¡¥×¥é¥¹¥Á¥Ã¥¯¥Ü¥È¥ë£¨¥×¥é¥è©`¥­(R)£©¡¡200mL×20Æ¿
¥ô¥£©`¥ó£³£ÇݔҺ¡¡¥×¥é¥¹¥Á¥Ã¥¯¥Ü¥È¥ë£¨¥×¥é¥è©`¥­(R)£©¡¡500mL×20Æ¿
ÖÆÔìÉÌ
Ð˺ÍÖêʽ»áÉç
×¢£ºÒÔÉÏÖÐÎÄ´¦·½×ÊÁϲ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ­´¦·½×ÊÁϸ½¼þ¡£
ÍêÕû˵Ã÷Ê鸽¼þ£º
https://www.kowa-souyaku.co.jp/file/4items_1206b.pdf
Clinical Experience with NIK-716 (Veen 3G Inj.) in Pediatrics.
Accession number£º02A0492432
Title£ºClinical Experience with NIK-716 (Veen 3G Inj.) in Pediatrics.
Author£ºMATSUNO KATSUNORI (Kurume Univ., Fac. of Med.) HIKITA SHIGEKI(Kurume Univ., Fac. of Med.) MIZOTE HIROYOSHI (Kurume Univ., Fac. of Med.)
Journal Title£ºJapanese Pharmacology & Therapeutics
Journal Code£ºZ0947A
ISSN£º0386-3603
VOL.30;NO.4;PAGE.319-325(2002)
Figure&Table&Reference£ºFIG.2, TBL.4, REF.20
Pub. Country£ºJapan
Language£ºJapanese
Abstract£ºThe maintenance fluid Veen 3G Inj., acetated electrolyte solution containing 5% glucose, was administered to postoperative pediatric patients who were judged to be completely or partially unable to take a maintenance fluid by the oral or enteral route and
require intravenous replacement of water, electrolytes and energy.
Veen 3G Inj. was administered by intravenous infusion for up to 24 hours from postoperative day 1 (POD 1). Blood chemistry examination and urinalysis were performed before and after administration to assess the following three variables:
1) the replacement and maintenance of water (assessment of hydration and urine output) ;
2) the maintenance of serum electrolytes (Na and K) ; and
3 the utilization of glucose (blood glucose and urinary glucose). Having these variables within normal range was regarded as the indicator of efficacy of a maintenance fluid. Veen 3G Inj.
proved effective in maintaining these variables within normal in all (100%) of the 25 pediatric patients who were eva luable for efficacy.
As for its safety, Veen 3G Inj. produced no adverse events or abnormal laboratory values attributable to its infusion in any of the 29 children who received it and was thus judged to have posed no safety problem. The results obtained in this study where Veen 3G Inj.
was administered to postoperative pediatric patients suggest that Veen 3G Inj. is a clinically useful and highly safe maintenance fluid.
(author abst.)   

¡¾´ó ÖРС¡¿¡¾´òÓ¡¡¿ ¡¾·±Ìå¡¿¡¾Í¶¸å¡¿¡¾Êղء¿ ¡¾ÍƼö¡¿¡¾¾Ù±¨¡¿¡¾ÆÀÂÛ¡¿ ¡¾¹Ø±Õ¡¿ ¡¾·µ»Ø¶¥²¿¡¿
·ÖÏíµ½QQ¿Õ¼ä
·ÖÏíµ½: 
ÉÏһƪ£ºVEEN-D INJ.(¥ô¥£©`¥ó£Ä×¢) ÏÂһƪ£ºVeen-3G Inj.200mL(´×ËáÄÆ/ÆÏÌÑÌÇ..

Ïà¹ØÀ¸Ä¿

×îÐÂÎÄÕÂ

ͼƬÖ÷Ìâ

ÈÈÃÅÎÄÕÂ

ÍƼöÎÄÕÂ